Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)
Brief Summary: Current management of patients with TIA (transient ischemic attack) or minor stroke includes the prompt investigation and treatment in the days and weeks after the event. However, new evidence shows patients are at the highest risk of stroke in the first few days after the TIA, with 50% of strokes which happen in the three months following TIA occurring within 48-72 hours. To date, there is no evidence to guide physicians on how to safely reduce this risk.

The FASTER trial is focusing on the initial period of high risk, starting patients on stroke prevention treatments in the hours following a TIA or minor stroke. The drugs to be tested have been shown to be effective in the similar setting of cardiology, reducing recurrent cardiac events in patients with unstable angina when commenced with the same speed after an event.

All patients will be on aspirin. The trial will see if adding another drug, clopidogrel, has an additional benefit in reducing the number of strokes after TIA or minor stroke within three months of TIA or minor stroke. It will also look if the very early introduction of simvastatin, a cholesterol lowering therapy, reduces stroke after TIA or minor stroke, both by itself and in addition to clopidogrel. The final aim of the trial is to ensure that these treatments are safe to be used in this population of patients.


Options:
A: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
B: Arm Label: ASS + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: clopidogrel | Arm Label: ASS + Plavix; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): ASS + Placebo, ASS + Plavix
C: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel, Drug: Aspirin | Arm Label: Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel placebo, Drug: Aspirin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination therapy | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Monotherapy | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Combination therapy, Monotherapy
D: Arm Label: Endeavor arm; Type: EXPERIMENTAL; Interventions: Device: Zotarolimus-eluting stent | Arm Label: Endeavor resolute arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Zotarolimus-eluting stent for ACS and DM | Arm Label: Xience arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Everolimus-eluting stent for long lesion | Arm Label: Cypher arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Sirolimus-eluting stent for short lesion | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent; Assigned to Arm(s): Endeavor arm | Intervention Type: DEVICE; Name: Zotarolimus-eluting stent for ACS and DM; Assigned to Arm(s): Endeavor resolute arm | Intervention Type: DEVICE; Name: Everolimus-eluting stent for long lesion; Assigned to Arm(s): Xience arm | Intervention Type: DEVICE; Name: Sirolimus-eluting stent for short lesion; Assigned to Arm(s): Cypher arm

Answer: A